

# Press Release

Abliva AB (publ), 556595-6538  
19 July 2024 08:30:00 CEST - Lund,  
Sweden



## Positive interim analysis in Abliva's FALCON study triggers convertible loan conversion

**Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial disease, today announced that the convertible loan of SEK 42 million pledged in the capital raise earlier this year will be converted into shares in the company. The convertible loan is converted following the positive outcome of the interim analysis of Wave 1 in the FALCON study, announced on July 18, 2024, and will provide Abliva with additional proceeds of SEK 42 million before transaction costs.**

Through the conversion of the convertible bonds into shares in the company and the convertible holders' payment of the cash contribution of in total approximately SEK 0.16 per share created through conversion, Abliva raises SEK 42 million before transaction costs, which are estimated to amount to approximately SEK 2.9 million.

Through the conversion of the convertible bonds into shares in the company, Abliva's share capital increases by SEK 13,125,000.00 from SEK 67,469,226.80 to SEK 80,594,226.80 and the number of shares increases by 262,500,000 shares from 1,349,384,536 shares to 1,611,884,536 shares.

The Board of Directors has decided to extend the payment period for the convertible holders' cash contribution of in total approximately SEK 0.16 per share created through conversion from within 5 banking days to within 15 banking days and the conversion of the convertible bonds into shares in the company is expected to be registered at the Swedish Companies Registration Office on or around 9 August 2024.

"The conversion of this convertible note was triggered with the successful (non-futile) interim analysis of the FALCON study and marks the completion of the financing round endorsed by the EGM on March 26. We are thankful for the continued support of our lead investors and shareholders as we progress KL1333 towards the market," said Ellen K. Donnelly, CEO of Abliva.

### **Abliva – Delivering mitochondrial health**

Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD<sup>+</sup> and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI). For more information, please visit [www.abliva.com](http://www.abliva.com). Subscribe to our [news](#) and follow us on [LinkedIn](#) and [YouTube](#).

**Abliva AB (publ)** - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol ABLI.

# Press Release

Abliva AB (publ), 556595-6538  
19 July 2024 08:30:00 CEST - Lund,  
Sweden



---

## For more information, please contact:

---

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations  
+46 (0)46-275 62 21, [ir@abliva.com](mailto:ir@abliva.com)

### **Abliva AB (publ)**

Medicon Village, SE-223 81 Lund, Sweden  
Tel: +46 (0)46 275 62 20 (switchboard)  
[info@abliva.com](mailto:info@abliva.com), [www.abliva.com](http://www.abliva.com)

## Attachments

---

[Positive interim analysis in Abliva's FALCON study triggers convertible loan conversion](#)